{"gene":"CXCL2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2018,"finding":"CXCL2 produced by transmigrating neutrophils is presented by the atypical chemokine receptor ACKR1 (enriched within endothelial junctions) to create a junctional chemokine 'depot' that enables efficient unidirectional luminal-to-abluminal neutrophil migration through venular walls, distinct from CXCL1 which guides luminal and sub-endothelial crawling.","method":"Confocal intravital microscopy, genetic mouse models (cell-specific knockouts), neutralizing antibodies","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic and antibody approaches, intravital imaging, multiple orthogonal methods in one rigorous study replicated across conditions","pmids":["30446388"],"is_preprint":false},{"year":2013,"finding":"CXCL2 (along with CXCL1) is released by mast cell granules (preformed) and newly synthesized via TLR4-dependent signaling; mast cells initiate early neutrophil recruitment and tissue macrophages sustain further neutrophil penetration, both through CXCL1/CXCL2-dependent chemotaxis shown by blocking monoclonal antibodies in vivo and in vitro chemotaxis assays.","method":"Mast cell-deficient mice, clodronate macrophage depletion, in vivo neutralizing antibodies, in vitro chemotaxis assays, intravital microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models and antibody blockade with orthogonal in vitro validation","pmids":["23645836"],"is_preprint":false},{"year":2013,"finding":"IL-1β-induced transcription of CXCL1 and CXCL2 genes in pancreatic β-cells requires NF-κB (p65/p50 subunits binding to consensus κB elements in both promoters) and serine-phosphorylated STAT1, with accompanying histone H3 modifications and increased RNA polymerase II phosphorylation.","method":"Promoter mutation analysis, ChIP assay, siRNA knockdown, reporter assays, Western blot","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — promoter mutagenesis, ChIP, and multiple orthogonal approaches in single study","pmids":["24280128"],"is_preprint":false},{"year":2010,"finding":"P2X7 receptor activation induces CXCL2 production in microglia through two parallel signaling pathways: NFAT activation and protein kinase C/MAPK (p38, ERK, JNK) pathways; PKC inhibitors suppressed ERK/JNK activation and CXCL2 expression, while MAPK inhibitors did not block NFAT activation.","method":"P2X7R agonist/antagonist pharmacology, NFAT inhibitor, MAPK inhibitors, PKC inhibitors, qPCR, ELISA","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors with orthogonal readouts, single lab","pmids":["20477948"],"is_preprint":false},{"year":2016,"finding":"Fli-1 (an Ets transcription factor) directly binds the CXCL2 promoter (shown by ChIP) and drives CXCL2 transcription in a dose-dependent manner in endothelial cells; Fli-1 siRNA knockdown reduces LPS/TNF-α-stimulated CXCL2 production, and Fli-1 acts additively with NF-κB p65 on CXCL2 promoter activation.","method":"ChIP assay, siRNA knockdown, transient transfection/reporter assay, ELISA","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct ChIP evidence of promoter binding plus functional reporter and knockdown experiments, single lab","pmids":["27889620"],"is_preprint":false},{"year":2014,"finding":"SIRT2 positively regulates LPS-induced CXCL2 expression in renal tubular cells: SIRT2 interacts with MKP-1 (MAPK phosphatase-1), and SIRT2 knockdown increases MKP-1 acetylation, suppresses p38 MAPK and JNK phosphorylation, and reduces p65 binding to the CXCL2 promoter, thereby decreasing CXCL2 production.","method":"Sirt2-/- mice, siRNA knockdown, adenoviral overexpression, co-immunoprecipitation, ChIP, Western blot","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal genetic KO and overexpression, co-IP, ChIP, multiple orthogonal methods in single study","pmids":["25349202"],"is_preprint":false},{"year":2008,"finding":"C. difficile toxin A induces CXCL2 expression in dendritic cells via p38 MAPK-dependent activation of IKK and NF-κB (p65/p50 heterodimers); p38 inhibition (SB203580 or siRNA) significantly reduced IKK activity, DC maturation, and CXCL2 upregulation, and NF-κB KO mice showed reduced CXCL2 expression and neutrophil chemoattraction.","method":"Pharmacological inhibitors, siRNA, NF-κB knockout mice, reporter assay, ELISA, chemotaxis assay","journal":"Journal of molecular medicine (Berlin, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological approaches with multiple readouts, single lab","pmids":["18985311"],"is_preprint":false},{"year":2011,"finding":"LPS induces CXCL2 transcription in bone marrow macrophages via p38, JNK, and NF-κB signaling pathways; c-Fos and p65 are directly recruited to the CXCL2 promoter (by ChIP); reactive oxygen species are required for CXCL2 secretion but not mRNA expression; CXCL2 from LPS-treated macrophages promotes osteoclast precursor migration and osteoclastogenesis, and CXCL2 neutralization prevents LPS-induced bone destruction in vivo.","method":"ChIP assay, signaling inhibitors, neutralizing antibodies, in vivo mouse model, osteoclastogenesis assay","journal":"Cytokine","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP demonstrating direct promoter binding, multiple inhibitors, in vivo validation with neutralizing antibodies","pmids":["21507677"],"is_preprint":false},{"year":2017,"finding":"CXCL1/CXCL2 acting through CXCR2 activates NLRP3 inflammasome in macrophages via a PKCμ-dependent integrin-linked kinase (ILK) pathway; siRNA knockdown or pharmacological inhibition of ILK or PKCμ compromised inflammasome activation and bioactive IL-1β production; in vivo CXCL1/CXCL2 blockade reduced M. tuberculosis-induced IL-1β.","method":"siRNA knockdown, pharmacological inhibitors, in vivo antibody blockade, in vivo mouse models","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological approaches in vitro plus in vivo confirmation, single lab","pmids":["28739876"],"is_preprint":false},{"year":2020,"finding":"Cxcl2 exists as monomers and dimers and signals through Cxcr2 via both G-protein and β-arrestin pathways; Cxcl2 variants showed higher Cxcr2 potency compared to Cxcl1 variants; native Cxcl1 bound heparan sulfate (HS) with higher affinity than native Cxcl2, but dimers bound HS with higher affinity than native proteins; peritoneal neutrophil recruitment is determined by complex interplay of Cxcr2 activation and GAG binding rather than either alone.","method":"Cellular CXCR2 G-protein and β-arrestin activity assays, HS binding assays, in vivo peritoneal recruitment, flow cytometry","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro receptor assays, binding assays, and in vivo functional studies with multiple orthogonal methods; replicated by same group with additional heterodimer study (PMID 37625009)","pmids":["32881070"],"is_preprint":false},{"year":2023,"finding":"The Cxcl1-Cxcl2 heterodimer is more potent at neutrophil recruitment than either individual chemokine; the heterodimer binds glycosaminoglycans with higher affinity than Cxcl1 or Cxcl2 alone and shows dampened CXCR2 receptor activity relative to its strong recruitment activity, suggesting optimal GAG interactions combined with dampened receptor desensitization promote robust recruitment.","method":"In vivo peritoneal neutrophil recruitment, CXCR2 cellular activity assays, GAG binding assays, flow cytometry","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods, single lab","pmids":["37625009"],"is_preprint":false},{"year":2008,"finding":"CXCL2 (MIP-2) acting on CXCR2 induces dose-dependent neurotoxicity in primary rat motor neurons; this toxicity is abrogated by the CXCR1/2 inhibitor reparixin and is absent in motor neurons from CXCR2-deficient mice, demonstrating direct CXCR2-dependent motor neuron death.","method":"Primary motor neuron cultures, pharmacological inhibition (reparixin), CXCR2 knockout mouse neurons, immunocytochemistry","journal":"Neuroimmunomodulation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic (CXCR2-KO) and pharmacological (reparixin) validation of receptor-dependent mechanism in primary cells","pmids":["18391506"],"is_preprint":false},{"year":2016,"finding":"IC-activated neutrophils express high levels of CXCL2, which amplifies neutrophil recruitment and activation in an autocrine/paracrine manner; neutralization of CXCL2 (but not CXCL1) in the interstitium effectively reduced neutrophil recruitment, establishing a CXCL2-driven positive-feedback loop distinct from tissue-resident cell-derived CXCL1.","method":"Multiphoton intravital microscopy, in vivo neutralizing antibodies, genomic approaches","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo neutralizing antibody with intravital imaging, single lab","pmids":["26802238"],"is_preprint":false},{"year":2019,"finding":"Neutrophils produce Cxcl2 (but not Cxcl1) in response to bacteria (GBS and other species) via multiple endosomal TLRs requiring UNC93B1 chaperone; simultaneous absence of TLR7, 9, and 13 recapitulates UNC93B1-defective phenotype; neutrophil-derived Cxcl2 acts autocrinously to amplify its own production and enhance antibacterial activities including oxygen radical release.","method":"Cell depletion experiments, UNC93B1-deficient mice, TLR7/9/13 triple KO mice, in vitro stimulation, in vivo peritonitis model","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (multiple KO lines) and functional approaches with in vitro/in vivo orthogonal validation","pmids":["31852751"],"is_preprint":false},{"year":2012,"finding":"CXCL2 produced by rotavirus-infected hepatic macrophages (not cholangiocytes) is the essential mediator of neutrophil chemotaxis; anti-Mip2/Cxcl2 antibodies completely prevented neutrophil chemotaxis induced by conditioned media from infected macrophages.","method":"In vitro infection of cell lines, conditioned media chemotaxis assay, neutralizing antibody depletion, PCR, ELISA, immunostaining","journal":"Pediatric research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody depletion of specific chemokine with functional readout, single lab","pmids":["20234283"],"is_preprint":false},{"year":2020,"finding":"Pregnane X receptor (PXR) suppresses CXCL2 transcription through both NF-κB and AP-1 binding sites in the Cxcl2 promoter; mutation of both NF-κB and AP-1 sites abolished PXR-dependent suppression in reporter assays; PXR agonist treatment in vivo reduced hepatic Cxcl2 expression and neutrophil infiltration.","method":"Reporter assays with wild-type and mutated Cxcl2 promoter, in vivo mouse treatment, qRT-PCR","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — promoter mutagenesis in reporter assay plus in vivo confirmation, single lab","pmids":["33076328"],"is_preprint":false},{"year":2012,"finding":"ERK2-dependent activation of c-Jun is required for NTHi-induced CXCL2 upregulation in inner ear spiral ligament fibrocytes; two AP-1 motifs in the CXCL2 5'-flanking region serve as NTHi-responsive elements, with the proximal AP-1 motif showing higher binding affinity for NTHi-activated c-Jun; CXCL2 release from fibrocytes recruits polymorphonuclear cells to the cochlea.","method":"MEK1/ERK2 inhibition, c-Jun knockdown, promoter binding analysis, chemotaxis assay","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding analysis, pharmacological inhibition, and functional chemotaxis assay, single lab","pmids":["22379036"],"is_preprint":false},{"year":2014,"finding":"Daidzein suppresses TNF-α-induced Cxcl2 transcription in murine lung epithelial cells by inhibiting PARP-1 activity, which reduces RelA/p65 protein PARylation required for NF-κB-driven Cxcl2 promoter activation; PARP-1 overexpression enhanced Cxcl2 promoter activity which was blocked by daidzein.","method":"Reporter assays (NF-κB-luc, Cxcl2-luc), PARP-1 expression plasmid transfection, Western blot/immunoprecipitation for PARylation, PARP-1 activity assay, in vivo mouse model","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — enzymatic activity assay, reporter assay with overexpression, in vivo confirmation, single lab","pmids":["24632845"],"is_preprint":false},{"year":2021,"finding":"A nucleus-localized lncRNA (lnc-Cxcl2) transcribed from the Cxcl2 gene locus acts in cis to inhibit Cxcl2 transcription in mouse lung epithelial cells by binding to the Cxcl2 promoter and recruiting ribonucleoprotein La, which inhibits chromatin accessibility; lnc-Cxcl2-deficient mice show increased Cxcl2 expression and more severe lung inflammation after influenza infection. (NOTE: This finding is about the lncRNA product, not the CXCL2 protein itself.)","method":"lnc-Cxcl2-deficient mice, chromatin accessibility assays, promoter binding analysis, RNA immunoprecipitation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Low","confidence_rationale":"Tier 2 / Moderate — but this describes a non-protein (lncRNA) product and its regulation of CXCL2; excluded from canonical protein mechanism per rules","pmids":["34607953"],"is_preprint":false},{"year":2023,"finding":"The secreted pseudo-serine protease PRSS35 suppresses CXCL2 protein levels through targeted proteolytic cleavage of a tandem lysine (KK) recognition motif on CXCL2; PRSS35 is processed by proprotein convertases to generate its active form; CXCL2 degradation by PRSS35 attenuates neutrophil recruitment and NET formation in HCC.","method":"In vitro protease cleavage assay, site-directed mutagenesis of cleavage motif, proprotein convertase assays, in vivo tumor models, immunoprecipitation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro cleavage reconstitution with mutagenesis of recognition motif plus in vivo functional validation","pmids":["36934105"],"is_preprint":false},{"year":2021,"finding":"Macrophage-derived extracellular vesicles carry CXCL2 on their surface, which recruits neutrophils in vitro and in vivo; CXCL2 on macrophage EVs activates the CXCR2/PKC/NOX4 signaling pathway in neutrophils to induce tissue damage.","method":"EV isolation, CXCL2 knockdown in macrophages, in vitro neutrophil chemotaxis, in vivo sepsis model, Western blot","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EV isolation with CXCL2 manipulation, in vitro and in vivo functional validation, single lab","pmids":["34507947"],"is_preprint":false},{"year":2018,"finding":"CXCL2-CXCR2 axis in CPT-11-resistant colon cancer cells signals through Gαi-2 and Gαq/11 G-proteins to promote cancer stem cell properties (CSC markers, EMT markers, MMPs); CXCL2 shRNA knockdown reduced CSC protein expression, cyclins, EMT markers, G-protein levels, and MMP expression.","method":"shRNA knockdown, double immunofluorescence, Western blot, colony-formation assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — shRNA knockdown with multiple molecular readouts identifying G-protein pathway, single lab","pmids":["30552676"],"is_preprint":false},{"year":2015,"finding":"Bone marrow adipocyte-conditioned media is a significant source of CXCL1 and CXCL2; both recombinant CXCL1 and CXCL2 accelerate osteoclast maturation via CXCR2 signaling, an effect blockable by neutralizing antibodies to either chemokine or by CXCR2 antagonist.","method":"In vitro osteoclastogenesis assay, adipocyte-conditioned media, neutralizing antibodies, CXCR2 antagonist, in vivo diet-induced adiposity models","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assay with receptor antagonist and neutralizing antibodies, in vivo correlations, single lab","pmids":["25802102"],"is_preprint":false},{"year":2012,"finding":"CXCL2 synthesized by oral squamous cell carcinoma cells promotes osteoclastic bone resorption by upregulating RANKL expression in stromal cells; anti-human CXCL2 neutralizing antibody dose-dependently blocked osteoclast induction by cancer cell-conditioned medium; recombinant CXCL2 directly increased RANKL expression in UAMS-32 stromal cells.","method":"Co-culture osteoclastogenesis assay, neutralizing antibody, recombinant CXCL2 treatment, in vivo xenograft model, microarray, immunohistochemistry","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blockade and recombinant protein in vitro plus in vivo xenograft validation, single lab","pmids":["22771802"],"is_preprint":false},{"year":2019,"finding":"CXCL2 inhibits osteoblast differentiation through inhibition of the ERK1/2 MAPK signaling pathway; ERK1/2 activation abolishes the inhibitory effect of CXCL2 on osteoblasts, while ERK1/2 inactivation reverses the pro-osteogenic effect of CXCL2 inhibition; CXCL2 neutralization in bone marrow alleviates bone loss in vivo.","method":"CXCL2 overexpression/knockdown in osteoblasts, ERK1/2 pharmacological activation/inhibition, in vivo antibody neutralization, Western blot, differentiation assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with pathway rescue experiments and in vivo neutralization, single lab","pmids":["31292171"],"is_preprint":false},{"year":2020,"finding":"CXCL2-CXCR2 signaling mediates colon cancer cell adhesion to ECM proteins (vitronectin, fibronectin, fibrinogen) via αV integrin in a CXCR2-dependent manner; immunoneutralization of αV integrin abolished CXCL2-triggered adhesion and inhibited peritoneal metastasis by 69% in vivo; CXCR2 antagonist reduced metastatic nodules by 70%.","method":"In vitro migration/proliferation assays, ECM adhesion assay, integrin subunit antibody blockade, in vivo peritoneal metastasis mouse model, CXCR2 antagonist (SB225002)","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor antagonist, integrin neutralization, and in vivo model with multiple orthogonal approaches, single lab","pmids":["34115261"],"is_preprint":false},{"year":2015,"finding":"Pressure force-induced CXCL2 and CCL2 expression in osteoblasts requires the IL-1β-MyD88 signaling axis; MyD88-/- osteoblasts fail to upregulate CXCL2 after pressure force; anti-IL-1β antibody impairs pressure-induced CXCL2 mRNA increases and MAP kinase phosphorylation in wild-type but not MyD88-/- osteoblasts.","method":"MyD88-/- primary osteoblasts, neutralizing anti-IL-1β antibody, recombinant IL-1β stimulation, MAP kinase phosphorylation assay, qRT-PCR","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus antibody neutralization and recombinant cytokine rescue, single lab","pmids":["25603464"],"is_preprint":false},{"year":2004,"finding":"Constitutive CXCL2/MIP-2 expression in normal mice is restricted to bone marrow and specifically to a Gr-1high, CD11b+, CD62Lhigh, CXCR2+ granulocyte subset (4-6% of total BM cells); in vitro BM stimulation does not increase the number of CXCL2-positive granulocytes; constitutive CXCL2 and CXCL1/KC expression patterns are tissue-specific and non-overlapping.","method":"RT-PCR, FACS analysis with intracellular staining, in vitro BM stimulation","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FACS with intracellular protein and surface marker co-staining, validated by RT-PCR across tissues, single lab","pmids":["15466452"],"is_preprint":false},{"year":2013,"finding":"Commensal bacteria selectively upregulate CXCL2 (but not CXCL1) in periodontal tissue in a MyD88-dependent manner, increasing neutrophil recruitment; neutrophil recruitment to gingival tissue is entirely CXCR2-dependent; germ-free mice show reduced CXCL2 but intact CXCL1 expression.","method":"Germ-free mice, CXCR2-KO mice, MyD88-KO mice, quantitative analysis of neutrophils and chemokines in gingival tissue","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic KO models with tissue-level chemokine and cell quantification, single lab","pmids":["23433011"],"is_preprint":false},{"year":2018,"finding":"IFNγ directly suppresses CXCL2 transcription in microglia and CNS-infiltrating myeloid cells, and suppresses CXCR2 transcription in CNS-infiltrating neutrophils; CXCL2 directly stimulates its own expression in neutrophils (autocrine/paracrine loop) enhanced by IL-1 and suppressed by IFNγ, determining anatomical location of CNS inflammatory infiltrates in EAE.","method":"IFNγR-KO mice, bone marrow chimeric mice, in vitro cultured neutrophils and macrophages with stimuli, qPCR, flow cytometry, immunohistochemistry, in situ hybridization","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mice, BM chimeras, in vitro mechanistic validation, and multiple orthogonal methods; IFNγ-CXCL2 autocrine loop directly tested","pmids":["30012158"],"is_preprint":false},{"year":2023,"finding":"HIF-1α activation (induced by cancer cell-secreted Ref-1) in Schwann cells induces CXCL2 expression; Schwann cell-derived CXCL2 drives macrophage migration via CXCR2; conditional knockdown of CXCL2 in Schwann cells attenuates cancer cell-induced macrophage recruitment and mechanical hypersensitivity in vivo.","method":"Co-culture assays, recombinant CXCL2, CXCR2 antagonist, anti-CXCL2 antibody, conditional Schwann cell CXCL2 knockdown, in vivo breast cancer perineural model","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional cell-type-specific knockdown in vivo plus in vitro receptor blockade, single lab","pmids":["36754246"],"is_preprint":false},{"year":2003,"finding":"CXCR2 physically associates with AMPA-type glutamate receptors (GluR1) as shown by co-immunoprecipitation in p7 cerebellar granule neurons and in HEK cells co-expressing both receptors; this association inhibits CXCL2-mediated chemotaxis, providing a molecular mechanism for the developmental loss of CXCL2 responsiveness in neurons.","method":"Co-immunoprecipitation, chemotaxis assay, CXCR2-expressing HEK cell transfection, primary cerebellar granule neuron cultures","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of CXCR2-AMPAR complex with functional chemotaxis consequence, single lab","pmids":["12507773"],"is_preprint":false},{"year":2023,"finding":"NFATc3 transcription factor regulates CXCL2 gene expression in macrophages; CXCL2 promoter-pGL3 luciferase reporter activity is enhanced by NFATc3 co-transfection; exogenous recombinant CXCL2 restores pulmonary fibrosis phenotype in NFATc3+/- mice, placing CXCL2 downstream of NFATc3 in macrophage-driven fibrosis.","method":"NFATc3 KO mice, luciferase reporter assay with NFATc3 co-transfection, adoptive macrophage transfer, in vitro cytokine stimulation, recombinant CXCL2 rescue experiment","journal":"Aging and disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay, genetic KO, adoptive transfer, and functional rescue, single lab","pmids":["37523510"],"is_preprint":false},{"year":2018,"finding":"CXCL2 binding to the glomerular endothelial glycocalyx is mediated by heparan sulfate (HS) in a domain-specific manner; CXCL2 and CXCL1 do not compete for the same HS binding sites on glomerular endothelial cells, with differential affinities determined by distinct HS domain structures, shown by competition ELISA with anti-HS scFv antibodies.","method":"Competition ELISA with HS preparations and anti-HS scFv antibodies on mouse glomerular endothelial cells (mGEnC-1)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-specific blocking with validated anti-HS antibodies, in vitro binding assay, single lab","pmids":["30248108"],"is_preprint":false},{"year":2010,"finding":"CXCL1 (KC) is required upstream of CXCL2 (MIP-2) expression in the lung during Klebsiella pneumoniae infection; KC-/- mice show reduced CXCL2 expression and diminished NF-κB and MAPK activation; in bone marrow-derived and alveolar macrophages, neutralizing KC decreases bacteria-induced MIP-2 production and NF-κB/MAPK activation.","method":"KC-/- mice, bone marrow-derived and alveolar macrophage cultures, KC neutralization, NF-κB/MAPK signaling assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and in vitro neutralization approaches, single lab","pmids":["20937845"],"is_preprint":false},{"year":2021,"finding":"CXCL2 overexpression in HCC cells induces apoptosis via both nuclear and mitochondrial apoptosis pathways and negatively regulates the cell cycle via ERK1/2 signaling; CXCL2 overexpression in vivo inhibited subcutaneous tumor growth in nude mice.","method":"Lentiviral overexpression, in vitro proliferation/apoptosis assays, ERK1/2 pathway analysis, in vivo xenograft model","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with pathway analysis and in vivo validation, single lab","pmids":["30293547"],"is_preprint":false},{"year":2017,"finding":"TIARP (a six-transmembrane protein) suppresses CXCL2 production by fibroblast-like synoviocytes and reduces CXCR1/CXCR2 expression on neutrophils; TIARP-/- FLS showed enhanced CXCL2 production upon TNF-α stimulation, and TIARP-/- neutrophils showed enhanced CXCL2-driven migration; IL-6R blockade in TIARP-/- mice attenuated arthritis and diminished neutrophil CXCL2-driven recruitment.","method":"TIARP-/- mice, DNA microarray, in vitro migration assay, anti-IL-6R antibody treatment, K/BxN serum transfer arthritis model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, in vitro functional assay, and in vivo therapeutic blockade, single lab","pmids":["27995997"],"is_preprint":false},{"year":2021,"finding":"CXCL2 secreted by microglia via CXCR2 promotes hippocampal neuronal ferroptosis (elevated MDA, decreased glutathione, iron accumulation, altered ferroptosis protein expression); rmCXCL2 induces microglia self-activation through CXCR2-NF-κB/NLRP3 signaling; CXCR2 antagonist SB225002 reverses CXCL2-induced ferroptosis.","method":"Recombinant CXCL2 treatment of neurons, CXCR2 antagonist (SB225002), ferroptosis markers (MDA, GSH, iron, protein levels), NF-κB/NLRP3 signaling assays, in vivo CLP model","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — recombinant protein and receptor antagonist with multiple molecular readouts, single lab","pmids":["39216299"],"is_preprint":false},{"year":2015,"finding":"miR-532-5p directly targets CXCL2 mRNA (validated by luciferase reporter assay) and negatively regulates CXCL2 expression in HCC; CXCL2 promotes HCC cell proliferation and metastasis, and miR-532-5p-mediated inhibition of these phenotypes is reversed by CXCL2 overexpression.","method":"Luciferase reporter assay (miR-532-5p target validation), miRNA overexpression/inhibition, cell proliferation and metastasis assays","journal":"American journal of translational research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct luciferase reporter validation of miRNA targeting plus functional rescue, single lab","pmids":["26807173"],"is_preprint":false},{"year":2015,"finding":"11β-HSD1 in cardiac fibroblasts suppresses CXCL2 (and CXCL5) expression; fibroblast fractions from Hsd11b1-/- hearts show elevated Cxcl2 post-MI; corticosterone or 11-dehydrocorticosterone (11β-HSD1 substrate) provision to cultured cardiac fibroblasts suppresses IL-1α-induced CXCL2 expression; bone marrow chimeras show this effect is attributable to host (non-bone marrow) cells.","method":"Hsd11b1-/- mice, bone marrow chimeras, cardiac fibroblast culture with glucocorticoid treatment, gene expression analysis","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, BM chimeras, and direct in vitro fibroblast treatment, single lab","pmids":["28522730"],"is_preprint":false}],"current_model":"CXCL2 is a secreted CXC chemokine that functions primarily as a potent neutrophil chemoattractant by binding and activating CXCR2 (via both G-protein and β-arrestin pathways) and interacting with heparan sulfate glycosaminoglycans in a domain-specific manner; it exists as monomers, homodimers, and Cxcl1-Cxcl2 heterodimers with distinct receptor potencies and GAG affinities; its transcription is regulated by NF-κB, STAT1, AP-1, Fli-1, NFATc3, SIRT2/MKP-1, and PXR acting on defined promoter elements; it is produced by neutrophils (via endosomal TLR/UNC93B1 signaling), macrophages (including via TRPM2 channel), mast cells (preformed in granules and newly synthesized via TLR4), fibroblasts, and other cells; it drives autocrine/paracrine positive-feedback loops in neutrophils amplifying its own production; it is presented by ACKR1 at endothelial junctions to guide neutrophil transmigration; it promotes osteoclastogenesis via RANKL upregulation and ERK/NF-κB pathways while inhibiting osteoblast differentiation via ERK1/2 suppression; it can be proteolytically degraded by the secreted protease PRSS35 at a tandem KK motif; its CXCR2-mediated signaling activates downstream pathways including PKC/MAPK, PI3K/AKT, and NLRP3 inflammasome in diverse cellular contexts."},"narrative":{"mechanistic_narrative":"CXCL2 is a secreted CXC chemokine that functions as a potent neutrophil chemoattractant, acting through the receptor CXCR2 to direct innate immune cell trafficking and to amplify inflammation [PMID:23645836, PMID:23433011]. It is produced by mast cells (preformed in granules and newly synthesized via TLR4), tissue macrophages, neutrophils, fibroblasts, microglia, and other cell types, and these distinct sources stage sequential and self-amplifying waves of neutrophil recruitment [PMID:23645836, PMID:31852751]. Neutrophil-derived CXCL2 establishes an autocrine/paracrine positive-feedback loop that amplifies its own production and enhances antibacterial functions including oxygen radical release [PMID:31852751, PMID:26802238, PMID:30012158]. During transmigration, CXCL2 deposited by migrating neutrophils is captured by the atypical chemokine receptor ACKR1 at endothelial junctions to create a chemokine depot that drives unidirectional luminal-to-abluminal migration, a role functionally distinct from CXCL1 [PMID:30446388]. CXCL2 exists as monomers, homodimers, and Cxcl1-Cxcl2 heterodimers with distinct CXCR2 potencies and heparan-sulfate affinities, and neutrophil recruitment is determined by the combined interplay of receptor activation and domain-specific glycosaminoglycan binding rather than either alone [PMID:32881070, PMID:37625009, PMID:30248108]. Through CXCR2, CXCL2 couples to G-protein and β-arrestin pathways and engages downstream PKC/MAPK, integrin-linked kinase, and NLRP3 inflammasome signaling in diverse contexts [PMID:32881070, PMID:28739876]. CXCL2 transcription is driven by NF-κB together with STAT1, AP-1/c-Jun, c-Fos, Fli-1, and NFATc3 acting on defined promoter elements, and is restrained by regulators including PXR, SIRT2/MKP-1, and IFNγ [PMID:24280128, PMID:27889620, PMID:22379036, PMID:21507677, PMID:37523510, PMID:33076328, PMID:25349202, PMID:30012158]. Beyond immunity, CXCL2 drives osteoclastogenesis by upregulating stromal RANKL and inhibits osteoblast differentiation through ERK1/2 suppression [PMID:22771802, PMID:31292171], and is degraded extracellularly by the secreted protease PRSS35 at a tandem lysine motif to limit neutrophil recruitment and NET formation [PMID:36934105].","teleology":[{"year":2004,"claim":"Establishing where CXCL2 is constitutively made was needed to distinguish baseline from inflammation-induced expression; mapping it to a defined bone marrow granulocyte subset showed CXCL2 production is cell-type-restricted and not simply inducible.","evidence":"RT-PCR and intracellular FACS with surface marker co-staining across mouse tissues","pmids":["15466452"],"confidence":"Medium","gaps":["Does not define the functional role of constitutive CXCL2 in the marrow granulocyte subset","No mechanism for tissue-restricted expression pattern"]},{"year":2008,"claim":"Linking CXCL2 induction to specific upstream signaling resolved how pathogen and danger stimuli converge on the gene; p38 MAPK-IKK-NF-κB and P2X7-driven NFAT/PKC-MAPK pathways were shown to drive CXCL2 transcription in dendritic cells and microglia.","evidence":"Pharmacological inhibitors, siRNA, NF-κB KO mice, reporter and chemotaxis assays","pmids":["18985311","20477948"],"confidence":"Medium","gaps":["Single-lab, single-stimulus contexts","Relative contribution of parallel pathways not quantified in vivo"]},{"year":2011,"claim":"Demonstrating direct recruitment of c-Fos and p65 to the CXCL2 promoter and linking macrophage CXCL2 to bone destruction connected transcriptional control to a pathological osteoclast phenotype.","evidence":"ChIP, signaling inhibitors, neutralizing antibodies, in vivo bone destruction model, osteoclastogenesis assays","pmids":["21507677"],"confidence":"High","gaps":["ROS requirement for secretion vs mRNA not mechanistically resolved","Promoter occupancy kinetics not addressed"]},{"year":2013,"claim":"Defining the cellular choreography of CXCL2 release answered how recruitment is initiated and sustained: mast cell granules and macrophages provide sequential CXCL1/CXCL2 sources, and microbial/IL-1β stimuli engage NF-κB/STAT1 in tissue cells.","evidence":"Mast cell-deficient and macrophage-depleted mice, neutralizing antibodies, intravital microscopy, promoter mutagenesis, ChIP, germ-free and MyD88-KO mice","pmids":["23645836","24280128","23433011"],"confidence":"High","gaps":["CXCL1 vs CXCL2 functional non-redundancy not fully dissected","Promoter findings tied to specific cell types only"]},{"year":2018,"claim":"Resolving CXCL2's spatial role in transmigration showed it is not merely a soluble gradient: ACKR1 captures neutrophil-derived CXCL2 at endothelial junctions to enforce directional migration, distinguishing it from CXCL1.","evidence":"Confocal intravital microscopy, cell-specific knockout mice, neutralizing antibodies","pmids":["30446388"],"confidence":"High","gaps":["Structural basis of ACKR1-CXCL2 presentation not defined","How the depot is released to abluminal side unresolved"]},{"year":2018,"claim":"Characterizing the biophysical interplay of receptor and matrix binding answered why monomer/dimer/heterodimer forms differ functionally; CXCL2 oligomeric state and domain-specific heparan sulfate binding jointly set recruitment potency.","evidence":"Competition ELISA with anti-HS antibodies, CXCR2 G-protein/β-arrestin assays, HS binding assays, in vivo recruitment","pmids":["30248108","32881070"],"confidence":"High","gaps":["Structural map of distinct HS-binding domains incomplete","In vivo oligomeric equilibrium not directly measured"]},{"year":2019,"claim":"Identifying neutrophil endosomal TLR/UNC93B1 control of CXCL2 and the IFNγ brake explained how the CXCL2 autocrine loop is selectively triggered and spatially constrained during infection and CNS inflammation.","evidence":"UNC93B1-deficient and TLR7/9/13 triple-KO mice, IFNγR-KO mice, BM chimeras, in vitro/in vivo stimulation","pmids":["31852751","30012158"],"confidence":"High","gaps":["Selectivity for CXCL2 over CXCL1 mechanism incomplete","Endosomal signaling-to-promoter link not fully traced"]},{"year":2023,"claim":"Defining the Cxcl1-Cxcl2 heterodimer as the most potent recruiter and identifying PRSS35 as an extracellular protease established both a gain-of-function ligand species and a post-secretion off-switch for CXCL2.","evidence":"In vivo neutrophil recruitment, GAG binding/CXCR2 assays, in vitro cleavage reconstitution with motif mutagenesis, proprotein convertase assays, tumor models","pmids":["37625009","36934105"],"confidence":"High","gaps":["Structural basis of heterodimer-CXCR2 dampening not solved","Physiological abundance and regulation of PRSS35-mediated turnover unquantified"]},{"year":null,"claim":"How CXCL2 oligomeric state, GAG presentation, ACKR1 depots, and extracellular proteolysis are integrated in vivo to set the magnitude and spatial precision of neutrophil recruitment remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified structural/quantitative model linking ligand form to receptor signaling output","Direct in vivo measurement of CXCL2 monomer/dimer/heterodimer ratios lacking","Generality of PRSS35 turnover across tissues unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[9,11,25,30]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[9,8]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,13,20,19]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,13]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,8,21]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,28]}],"complexes":[],"partners":["CXCR2","ACKR1","PRSS35"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P19875","full_name":"C-X-C motif chemokine 2","aliases":["Growth-regulated protein beta","Gro-beta","Macrophage inflammatory protein 2-alpha","MIP2-alpha"],"length_aa":107,"mass_kda":11.4,"function":"Produced by activated monocytes and neutrophils and expressed at sites of inflammation. Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P19875/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL2","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL2","total_profiled":1310},"omim":[{"mim_id":"616560","title":"CD300H ANTIGEN; CD300H","url":"https://www.omim.org/entry/616560"},{"mim_id":"614995","title":"INTERLEUKIN 17 RECEPTOR E; IL17RE","url":"https://www.omim.org/entry/614995"},{"mim_id":"612252","title":"C-TYPE LECTIN DOMAIN FAMILY 9, MEMBER A; CLEC9A","url":"https://www.omim.org/entry/612252"},{"mim_id":"611184","title":"PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1; PIEZO1","url":"https://www.omim.org/entry/611184"},{"mim_id":"611162","title":"MALARIA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/611162"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":537.4}],"url":"https://www.proteinatlas.org/search/CXCL2"},"hgnc":{"alias_symbol":["SCYB2","GROb","MIP-2a","MGSA-b","CINC-2a"],"prev_symbol":["GRO2"]},"alphafold":{"accession":"P19875","domains":[{"cath_id":"2.40.50.40","chopping":"53-105","consensus_level":"high","plddt":91.2545,"start":53,"end":105}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19875","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19875-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19875-F1-predicted_aligned_error_v6.png","plddt_mean":81.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL2","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL2"},"sequence":{"accession":"P19875","fasta_url":"https://rest.uniprot.org/uniprotkb/P19875.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19875/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19875"}},"corpus_meta":[{"pmid":"23645836","id":"PMC_23645836","title":"Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23645836","citation_count":739,"is_preprint":false},{"pmid":"30446388","id":"PMC_30446388","title":"Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30446388","citation_count":286,"is_preprint":false},{"pmid":"24280128","id":"PMC_24280128","title":"NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription.","date":"2013","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24280128","citation_count":149,"is_preprint":false},{"pmid":"20477948","id":"PMC_20477948","title":"P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways.","date":"2010","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20477948","citation_count":131,"is_preprint":false},{"pmid":"25802102","id":"PMC_25802102","title":"Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer.","date":"2015","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/25802102","citation_count":130,"is_preprint":false},{"pmid":"28739876","id":"PMC_28739876","title":"CXCL1 and CXCL2 Regulate NLRP3 Inflammasome Activation via G-Protein-Coupled Receptor CXCR2.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28739876","citation_count":129,"is_preprint":false},{"pmid":"32881070","id":"PMC_32881070","title":"Neutrophil recruitment by chemokines Cxcl1/KC and Cxcl2/MIP2: Role of Cxcr2 activation and glycosaminoglycan interactions.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32881070","citation_count":119,"is_preprint":false},{"pmid":"23904157","id":"PMC_23904157","title":"Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23904157","citation_count":115,"is_preprint":false},{"pmid":"20937845","id":"PMC_20937845","title":"CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20937845","citation_count":111,"is_preprint":false},{"pmid":"36859354","id":"PMC_36859354","title":"PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36859354","citation_count":103,"is_preprint":false},{"pmid":"23372021","id":"PMC_23372021","title":"Roles of chemokine ligand-2 (CXCL2) and neutrophils in influencing endothelial cell function and inflammation of human adipose tissue.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23372021","citation_count":95,"is_preprint":false},{"pmid":"20162422","id":"PMC_20162422","title":"Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival.","date":"2010","source":"International journal of colorectal disease","url":"https://pubmed.ncbi.nlm.nih.gov/20162422","citation_count":94,"is_preprint":false},{"pmid":"23433011","id":"PMC_23433011","title":"Commensal bacteria-dependent select expression of CXCL2 contributes to periodontal tissue homeostasis.","date":"2013","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/23433011","citation_count":93,"is_preprint":false},{"pmid":"35541899","id":"PMC_35541899","title":"SNAIL Induces EMT and Lung Metastasis of Tumours Secreting CXCL2 to Promote the Invasion of M2-Type Immunosuppressed Macrophages in Colorectal Cancer.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35541899","citation_count":91,"is_preprint":false},{"pmid":"17460147","id":"PMC_17460147","title":"Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2.","date":"2007","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/17460147","citation_count":90,"is_preprint":false},{"pmid":"33829508","id":"PMC_33829508","title":"Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33829508","citation_count":86,"is_preprint":false},{"pmid":"25349202","id":"PMC_25349202","title":"SIRT2 Regulates LPS-Induced Renal Tubular CXCL2 and CCL2 Expression.","date":"2014","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/25349202","citation_count":80,"is_preprint":false},{"pmid":"16522746","id":"PMC_16522746","title":"Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain.","date":"2006","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16522746","citation_count":79,"is_preprint":false},{"pmid":"24795505","id":"PMC_24795505","title":"The macrophage inflammatory proteins MIP1α (CCL3) and MIP2α (CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24795505","citation_count":79,"is_preprint":false},{"pmid":"30259595","id":"PMC_30259595","title":"Chemokine (C-X-C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid-derived suppressor cells.","date":"2018","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/30259595","citation_count":71,"is_preprint":false},{"pmid":"37695548","id":"PMC_37695548","title":"Single-cell immune profiling of mouse liver aging reveals Cxcl2+ macrophages recruit neutrophils to aggravate liver injury.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/37695548","citation_count":70,"is_preprint":false},{"pmid":"26802238","id":"PMC_26802238","title":"Neutrophils Self-Regulate Immune Complex-Mediated Cutaneous Inflammation through CXCL2.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26802238","citation_count":64,"is_preprint":false},{"pmid":"17255321","id":"PMC_17255321","title":"CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.","date":"2007","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17255321","citation_count":63,"is_preprint":false},{"pmid":"18985311","id":"PMC_18985311","title":"Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway.","date":"2008","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/18985311","citation_count":59,"is_preprint":false},{"pmid":"26807173","id":"PMC_26807173","title":"Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC.","date":"2015","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/26807173","citation_count":59,"is_preprint":false},{"pmid":"31522017","id":"PMC_31522017","title":"RvD1 ameliorates LPS-induced acute lung injury via the suppression of neutrophil infiltration by reducing CXCL2 expression and release from resident alveolar macrophages.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31522017","citation_count":58,"is_preprint":false},{"pmid":"32769172","id":"PMC_32769172","title":"Functional heterogeneity of alveolar macrophage population based on expression of CXCL2.","date":"2020","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32769172","citation_count":57,"is_preprint":false},{"pmid":"30552676","id":"PMC_30552676","title":"CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30552676","citation_count":57,"is_preprint":false},{"pmid":"25708728","id":"PMC_25708728","title":"Autophagy Mediates HBx-Induced Nuclear Factor-κB Activation and Release of IL-6, IL-8, and CXCL2 in Hepatocytes.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25708728","citation_count":56,"is_preprint":false},{"pmid":"36934105","id":"PMC_36934105","title":"Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36934105","citation_count":53,"is_preprint":false},{"pmid":"34507947","id":"PMC_34507947","title":"Macrophagic Extracellular Vesicle CXCL2 Recruits and Activates the Neutrophil CXCR2/PKC/NOX4 Axis in Sepsis.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/34507947","citation_count":51,"is_preprint":false},{"pmid":"22397722","id":"PMC_22397722","title":"CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro.","date":"2012","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/22397722","citation_count":51,"is_preprint":false},{"pmid":"20234283","id":"PMC_20234283","title":"Macrophages are targeted by rotavirus in experimental biliary atresia and induce neutrophil chemotaxis by Mip2/Cxcl2.","date":"2010","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/20234283","citation_count":49,"is_preprint":false},{"pmid":"38637499","id":"PMC_38637499","title":"The role of CXCL2-mediated crosstalk between tumor cells and macrophages in Fusobacterium nucleatum-promoted oral squamous cell carcinoma progression.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38637499","citation_count":48,"is_preprint":false},{"pmid":"32439934","id":"PMC_32439934","title":"Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2-VEGFA axis.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32439934","citation_count":48,"is_preprint":false},{"pmid":"22615136","id":"PMC_22615136","title":"Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22615136","citation_count":47,"is_preprint":false},{"pmid":"33076328","id":"PMC_33076328","title":"PXR Functionally Interacts with NF-κB and AP-1 to Downregulate the Inflammation-Induced Expression of Chemokine CXCL2 in Mice.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33076328","citation_count":47,"is_preprint":false},{"pmid":"24659080","id":"PMC_24659080","title":"Suppression of CXCL2 upregulation underlies the therapeutic effect of the retinoid Am80 on intracerebral hemorrhage in mice.","date":"2014","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/24659080","citation_count":47,"is_preprint":false},{"pmid":"31752549","id":"PMC_31752549","title":"CXCL2, a new critical factor and therapeutic target for cardiovascular diseases.","date":"2019","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31752549","citation_count":45,"is_preprint":false},{"pmid":"33807899","id":"PMC_33807899","title":"The CXCL2/IL8/CXCR2 Pathway Is Relevant for Brain Tumor Malignancy and Endothelial Cell Function.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33807899","citation_count":44,"is_preprint":false},{"pmid":"34721432","id":"PMC_34721432","title":"Decreased miR-4512 Levels in Monocytes and Macrophages of Individuals With Systemic Lupus Erythematosus Contribute to Innate Immune Activation and Neutrsophil NETosis by Targeting TLR4 and CXCL2.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34721432","citation_count":43,"is_preprint":false},{"pmid":"32230838","id":"PMC_32230838","title":"Herbal Combinational Medication of Glycyrrhiza glabra, Agastache rugosa Containing Glycyrrhizic Acid, Tilianin Inhibits Neutrophilic Lung Inflammation by Affecting CXCL2, Interleukin-17/STAT3 Signal Pathways in a Murine Model of COPD.","date":"2020","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/32230838","citation_count":43,"is_preprint":false},{"pmid":"36754246","id":"PMC_36754246","title":"Schwann cell-derived CXCL2 contributes to cancer pain by modulating macrophage infiltration in a mouse breast cancer model.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36754246","citation_count":42,"is_preprint":false},{"pmid":"30251149","id":"PMC_30251149","title":"TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression.","date":"2018","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/30251149","citation_count":42,"is_preprint":false},{"pmid":"31810929","id":"PMC_31810929","title":"The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.","date":"2019","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31810929","citation_count":41,"is_preprint":false},{"pmid":"34115261","id":"PMC_34115261","title":"CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.","date":"2021","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/34115261","citation_count":39,"is_preprint":false},{"pmid":"34607953","id":"PMC_34607953","title":"Cis-acting lnc-Cxcl2 restrains neutrophil-mediated lung inflammation by inhibiting epithelial cell CXCL2 expression in virus infection.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34607953","citation_count":38,"is_preprint":false},{"pmid":"22342618","id":"PMC_22342618","title":"Induction of TNF-alfa and CXCL-2 mRNAs in different organs of mice infected with pathogenic Leptospira.","date":"2012","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22342618","citation_count":38,"is_preprint":false},{"pmid":"18391506","id":"PMC_18391506","title":"Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures.","date":"2008","source":"Neuroimmunomodulation","url":"https://pubmed.ncbi.nlm.nih.gov/18391506","citation_count":38,"is_preprint":false},{"pmid":"30904573","id":"PMC_30904573","title":"IL-10 and CXCL2 in trigeminal ganglia in neuropathic pain.","date":"2019","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30904573","citation_count":37,"is_preprint":false},{"pmid":"40197328","id":"PMC_40197328","title":"CXCL2: a key player in the tumor microenvironment and inflammatory diseases.","date":"2025","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/40197328","citation_count":37,"is_preprint":false},{"pmid":"31927212","id":"PMC_31927212","title":"The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.","date":"2020","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/31927212","citation_count":37,"is_preprint":false},{"pmid":"27889620","id":"PMC_27889620","title":"The Fli-1 transcription factor is a critical regulator for controlling the expression of chemokine C-X-C motif ligand 2 (CXCL2).","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27889620","citation_count":37,"is_preprint":false},{"pmid":"30201769","id":"PMC_30201769","title":"TRPM2 Exacerbates Central Nervous System Inflammation in Experimental Autoimmune Encephalomyelitis by Increasing Production of CXCL2 Chemokines.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30201769","citation_count":37,"is_preprint":false},{"pmid":"30871526","id":"PMC_30871526","title":"Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.","date":"2019","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/30871526","citation_count":36,"is_preprint":false},{"pmid":"31852751","id":"PMC_31852751","title":"Neutrophils Enhance Their Own Influx to Sites of Bacterial Infection via Endosomal TLR-Dependent Cxcl2 Production.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31852751","citation_count":36,"is_preprint":false},{"pmid":"30293547","id":"PMC_30293547","title":"Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma.","date":"2018","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/30293547","citation_count":35,"is_preprint":false},{"pmid":"21507677","id":"PMC_21507677","title":"CXCL2 mediates lipopolysaccharide-induced osteoclastogenesis in RANKL-primed precursors.","date":"2011","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/21507677","citation_count":34,"is_preprint":false},{"pmid":"37318712","id":"PMC_37318712","title":"Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression.","date":"2023","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37318712","citation_count":33,"is_preprint":false},{"pmid":"30012158","id":"PMC_30012158","title":"An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE.","date":"2018","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/30012158","citation_count":33,"is_preprint":false},{"pmid":"38605400","id":"PMC_38605400","title":"METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/38605400","citation_count":32,"is_preprint":false},{"pmid":"27013641","id":"PMC_27013641","title":"Site-Specific Neutrophil Migration and CXCL2 Expression in Periodontal Tissue.","date":"2016","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/27013641","citation_count":31,"is_preprint":false},{"pmid":"34108959","id":"PMC_34108959","title":"Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34108959","citation_count":31,"is_preprint":false},{"pmid":"28522730","id":"PMC_28522730","title":"11β-HSD1 suppresses cardiac fibroblast CXCL2, CXCL5 and neutrophil recruitment to the heart post MI.","date":"2017","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28522730","citation_count":31,"is_preprint":false},{"pmid":"25261746","id":"PMC_25261746","title":"Critical role of MKP-1 in lipopolysaccharide-induced osteoclast formation through CXCL1 and CXCL2.","date":"2014","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/25261746","citation_count":31,"is_preprint":false},{"pmid":"33010041","id":"PMC_33010041","title":"Increased expression of CXCL2 in ACPA-positive rheumatoid arthritis and its role in osteoclastogenesis.","date":"2020","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33010041","citation_count":28,"is_preprint":false},{"pmid":"37121164","id":"PMC_37121164","title":"Sirt4 deficiency promotes the development of atherosclerosis by activating the NF-κB/IκB/CXCL2/3 pathway.","date":"2023","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/37121164","citation_count":28,"is_preprint":false},{"pmid":"34171415","id":"PMC_34171415","title":"Cathepsin C aggravates neuroinflammation via promoting production of CCL2 and CXCL2 in glial cells and neurons in a cryogenic brain lesion.","date":"2021","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/34171415","citation_count":28,"is_preprint":false},{"pmid":"22771802","id":"PMC_22771802","title":"CXCL2 synthesized by oral squamous cell carcinoma is involved in cancer-associated bone destruction.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22771802","citation_count":28,"is_preprint":false},{"pmid":"31292171","id":"PMC_31292171","title":"CXCL2 attenuates osteoblast differentiation by inhibiting the ERK1/2 signaling pathway.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31292171","citation_count":27,"is_preprint":false},{"pmid":"30564899","id":"PMC_30564899","title":"Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma.","date":"2018","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30564899","citation_count":27,"is_preprint":false},{"pmid":"24632845","id":"PMC_24632845","title":"Daidzein suppresses pro-inflammatory chemokine Cxcl2 transcription in TNF-α-stimulated murine lung epithelial cells via depressing PARP-1 activity.","date":"2014","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/24632845","citation_count":26,"is_preprint":false},{"pmid":"27117207","id":"PMC_27117207","title":"Type conversion of secretomes in a 3D TAM2 and HCC cell co-culture system and functional importance of CXCL2 in HCC.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27117207","citation_count":23,"is_preprint":false},{"pmid":"36933379","id":"PMC_36933379","title":"Xuanfei Baidu Decoction regulates NETs formation via CXCL2/CXCR2 signaling pathway that is involved in acute lung injury.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36933379","citation_count":23,"is_preprint":false},{"pmid":"37523510","id":"PMC_37523510","title":"NFATc3 Promotes Pulmonary Inflammation and Fibrosis by Regulating Production of CCL2 and CXCL2 in Macrophages.","date":"2023","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/37523510","citation_count":22,"is_preprint":false},{"pmid":"17944017","id":"PMC_17944017","title":"A CXCL2 polymorphism is associated with better outcomes in patients with severe sepsis.","date":"2007","source":"Critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17944017","citation_count":22,"is_preprint":false},{"pmid":"37625009","id":"PMC_37625009","title":"Chemokine Cxcl1-Cxcl2 heterodimer is a potent neutrophil chemoattractant.","date":"2023","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/37625009","citation_count":21,"is_preprint":false},{"pmid":"16684516","id":"PMC_16684516","title":"Theiler's virus induces the MIP-2 chemokine (CXCL2) in astrocytes from genetically susceptible but not from resistant mouse strains.","date":"2006","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16684516","citation_count":21,"is_preprint":false},{"pmid":"36880752","id":"PMC_36880752","title":"Staphylococcus aureus Infection Induces the Production of the Neutrophil Chemoattractants CXCL1, CXCL2, CXCL3, CXCL5, CCL3, and CCL7 by Murine Osteoblasts.","date":"2023","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36880752","citation_count":19,"is_preprint":false},{"pmid":"25603464","id":"PMC_25603464","title":"Induction of CXCL2 and CCL2 by pressure force requires IL-1β-MyD88 axis in osteoblasts.","date":"2015","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/25603464","citation_count":19,"is_preprint":false},{"pmid":"16421598","id":"PMC_16421598","title":"A CXCL2 tandem repeat promoter polymorphism is associated with susceptibility to severe sepsis in the Spanish population.","date":"2006","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16421598","citation_count":19,"is_preprint":false},{"pmid":"15466452","id":"PMC_15466452","title":"Constitutive expression of CXCL2/MIP-2 is restricted to a Gr-1high, CD11b+, CD62Lhigh subset of bone marrow derived granulocytes.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15466452","citation_count":19,"is_preprint":false},{"pmid":"21621198","id":"PMC_21621198","title":"Expression of the inflammatory chemokines CCL2, CCL5 and CXCL2 and the receptors CCR1-3 and CXCR2 in T lymphocytes from mammary tumor-bearing mice.","date":"2011","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21621198","citation_count":18,"is_preprint":false},{"pmid":"23553435","id":"PMC_23553435","title":"NTHi induction of Cxcl2 and middle ear mucosal metaplasia in mice.","date":"2013","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/23553435","citation_count":18,"is_preprint":false},{"pmid":"36577281","id":"PMC_36577281","title":"Tumor-associated macrophages mediate gastrointestinal stromal tumor cell metastasis through CXCL2/CXCR2.","date":"2022","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36577281","citation_count":17,"is_preprint":false},{"pmid":"35116406","id":"PMC_35116406","title":"An inter-correlation among chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2 and CXCL8, and their diversified potential as biomarkers for tumor features and survival profiles in non-small cell lung cancer patients.","date":"2021","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35116406","citation_count":17,"is_preprint":false},{"pmid":"22379036","id":"PMC_22379036","title":"ERK2-dependent activation of c-Jun is required for nontypeable Haemophilus influenzae-induced CXCL2 upregulation in inner ear fibrocytes.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22379036","citation_count":17,"is_preprint":false},{"pmid":"27995997","id":"PMC_27995997","title":"TIARP attenuates autoantibody-mediated arthritis via the suppression of neutrophil migration by reducing CXCL2/CXCR2 and IL-6 expression.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27995997","citation_count":16,"is_preprint":false},{"pmid":"34474677","id":"PMC_34474677","title":"CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.","date":"2021","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/34474677","citation_count":15,"is_preprint":false},{"pmid":"33575480","id":"PMC_33575480","title":"CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.","date":"2020","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/33575480","citation_count":15,"is_preprint":false},{"pmid":"28053238","id":"PMC_28053238","title":"Steroid Receptor Coactivator 3 Contributes to Host Defense against Enteric Bacteria by Recruiting Neutrophils via Upregulation of CXCL2 Expression.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28053238","citation_count":15,"is_preprint":false},{"pmid":"30248108","id":"PMC_30248108","title":"Differential binding of chemokines CXCL1, CXCL2 and CCL2 to mouse glomerular endothelial cells reveals specificity for distinct heparan sulfate domains.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30248108","citation_count":15,"is_preprint":false},{"pmid":"39216299","id":"PMC_39216299","title":"Quercetin protects against sepsis-associated encephalopathy by inhibiting microglia-neuron crosstalk via the CXCL2/CXCR2 signaling pathway.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39216299","citation_count":14,"is_preprint":false},{"pmid":"32308429","id":"PMC_32308429","title":"Tripterine Restrains the Aggressiveness of Hepatocellular Carcinoma Cell via Regulating miRNA-532-5p/CXCL2 Axis.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32308429","citation_count":14,"is_preprint":false},{"pmid":"36681054","id":"PMC_36681054","title":"Herbal formula Jiawei Xiaochengqi decoction prevents postoperative abdominal adhesion in a rat model through inhibition of CXCL2-CXCR2 pathway.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36681054","citation_count":14,"is_preprint":false},{"pmid":"30707086","id":"PMC_30707086","title":"Staphylococcus aureus infected embolic stroke upregulates Orm1 and Cxcl2 in a rat model of septic stroke pathology.","date":"2019","source":"Neurological research","url":"https://pubmed.ncbi.nlm.nih.gov/30707086","citation_count":14,"is_preprint":false},{"pmid":"27194111","id":"PMC_27194111","title":"Curcumin Inhibits 5-Fluorouracil-induced Up-regulation of CXCL1 and CXCL2 of the Colon Associated with Attenuation of Diarrhoea Development.","date":"2016","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27194111","citation_count":14,"is_preprint":false},{"pmid":"36276119","id":"PMC_36276119","title":"Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36276119","citation_count":13,"is_preprint":false},{"pmid":"27351827","id":"PMC_27351827","title":"Retinoic acid receptor agonist Am80 inhibits CXCL2 production from microglial BV-2 cells via attenuation of NF-κB signaling.","date":"2016","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27351827","citation_count":13,"is_preprint":false},{"pmid":"12507773","id":"PMC_12507773","title":"Expression of AMPA-type glutamate receptors in HEK cells and cerebellar granule neurons impairs CXCL2-mediated chemotaxis.","date":"2003","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/12507773","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58273,"output_tokens":10763,"usd":0.168132,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21063,"output_tokens":3502,"usd":0.096433,"stage2_stop_reason":"end_turn"},"total_usd":0.264565,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL2 produced by transmigrating neutrophils is presented by the atypical chemokine receptor ACKR1 (enriched within endothelial junctions) to create a junctional chemokine 'depot' that enables efficient unidirectional luminal-to-abluminal neutrophil migration through venular walls, distinct from CXCL1 which guides luminal and sub-endothelial crawling.\",\n      \"method\": \"Confocal intravital microscopy, genetic mouse models (cell-specific knockouts), neutralizing antibodies\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic and antibody approaches, intravital imaging, multiple orthogonal methods in one rigorous study replicated across conditions\",\n      \"pmids\": [\"30446388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CXCL2 (along with CXCL1) is released by mast cell granules (preformed) and newly synthesized via TLR4-dependent signaling; mast cells initiate early neutrophil recruitment and tissue macrophages sustain further neutrophil penetration, both through CXCL1/CXCL2-dependent chemotaxis shown by blocking monoclonal antibodies in vivo and in vitro chemotaxis assays.\",\n      \"method\": \"Mast cell-deficient mice, clodronate macrophage depletion, in vivo neutralizing antibodies, in vitro chemotaxis assays, intravital microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models and antibody blockade with orthogonal in vitro validation\",\n      \"pmids\": [\"23645836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-1β-induced transcription of CXCL1 and CXCL2 genes in pancreatic β-cells requires NF-κB (p65/p50 subunits binding to consensus κB elements in both promoters) and serine-phosphorylated STAT1, with accompanying histone H3 modifications and increased RNA polymerase II phosphorylation.\",\n      \"method\": \"Promoter mutation analysis, ChIP assay, siRNA knockdown, reporter assays, Western blot\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — promoter mutagenesis, ChIP, and multiple orthogonal approaches in single study\",\n      \"pmids\": [\"24280128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"P2X7 receptor activation induces CXCL2 production in microglia through two parallel signaling pathways: NFAT activation and protein kinase C/MAPK (p38, ERK, JNK) pathways; PKC inhibitors suppressed ERK/JNK activation and CXCL2 expression, while MAPK inhibitors did not block NFAT activation.\",\n      \"method\": \"P2X7R agonist/antagonist pharmacology, NFAT inhibitor, MAPK inhibitors, PKC inhibitors, qPCR, ELISA\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors with orthogonal readouts, single lab\",\n      \"pmids\": [\"20477948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Fli-1 (an Ets transcription factor) directly binds the CXCL2 promoter (shown by ChIP) and drives CXCL2 transcription in a dose-dependent manner in endothelial cells; Fli-1 siRNA knockdown reduces LPS/TNF-α-stimulated CXCL2 production, and Fli-1 acts additively with NF-κB p65 on CXCL2 promoter activation.\",\n      \"method\": \"ChIP assay, siRNA knockdown, transient transfection/reporter assay, ELISA\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct ChIP evidence of promoter binding plus functional reporter and knockdown experiments, single lab\",\n      \"pmids\": [\"27889620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SIRT2 positively regulates LPS-induced CXCL2 expression in renal tubular cells: SIRT2 interacts with MKP-1 (MAPK phosphatase-1), and SIRT2 knockdown increases MKP-1 acetylation, suppresses p38 MAPK and JNK phosphorylation, and reduces p65 binding to the CXCL2 promoter, thereby decreasing CXCL2 production.\",\n      \"method\": \"Sirt2-/- mice, siRNA knockdown, adenoviral overexpression, co-immunoprecipitation, ChIP, Western blot\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal genetic KO and overexpression, co-IP, ChIP, multiple orthogonal methods in single study\",\n      \"pmids\": [\"25349202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"C. difficile toxin A induces CXCL2 expression in dendritic cells via p38 MAPK-dependent activation of IKK and NF-κB (p65/p50 heterodimers); p38 inhibition (SB203580 or siRNA) significantly reduced IKK activity, DC maturation, and CXCL2 upregulation, and NF-κB KO mice showed reduced CXCL2 expression and neutrophil chemoattraction.\",\n      \"method\": \"Pharmacological inhibitors, siRNA, NF-κB knockout mice, reporter assay, ELISA, chemotaxis assay\",\n      \"journal\": \"Journal of molecular medicine (Berlin, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological approaches with multiple readouts, single lab\",\n      \"pmids\": [\"18985311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LPS induces CXCL2 transcription in bone marrow macrophages via p38, JNK, and NF-κB signaling pathways; c-Fos and p65 are directly recruited to the CXCL2 promoter (by ChIP); reactive oxygen species are required for CXCL2 secretion but not mRNA expression; CXCL2 from LPS-treated macrophages promotes osteoclast precursor migration and osteoclastogenesis, and CXCL2 neutralization prevents LPS-induced bone destruction in vivo.\",\n      \"method\": \"ChIP assay, signaling inhibitors, neutralizing antibodies, in vivo mouse model, osteoclastogenesis assay\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP demonstrating direct promoter binding, multiple inhibitors, in vivo validation with neutralizing antibodies\",\n      \"pmids\": [\"21507677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL1/CXCL2 acting through CXCR2 activates NLRP3 inflammasome in macrophages via a PKCμ-dependent integrin-linked kinase (ILK) pathway; siRNA knockdown or pharmacological inhibition of ILK or PKCμ compromised inflammasome activation and bioactive IL-1β production; in vivo CXCL1/CXCL2 blockade reduced M. tuberculosis-induced IL-1β.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibitors, in vivo antibody blockade, in vivo mouse models\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological approaches in vitro plus in vivo confirmation, single lab\",\n      \"pmids\": [\"28739876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cxcl2 exists as monomers and dimers and signals through Cxcr2 via both G-protein and β-arrestin pathways; Cxcl2 variants showed higher Cxcr2 potency compared to Cxcl1 variants; native Cxcl1 bound heparan sulfate (HS) with higher affinity than native Cxcl2, but dimers bound HS with higher affinity than native proteins; peritoneal neutrophil recruitment is determined by complex interplay of Cxcr2 activation and GAG binding rather than either alone.\",\n      \"method\": \"Cellular CXCR2 G-protein and β-arrestin activity assays, HS binding assays, in vivo peritoneal recruitment, flow cytometry\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro receptor assays, binding assays, and in vivo functional studies with multiple orthogonal methods; replicated by same group with additional heterodimer study (PMID 37625009)\",\n      \"pmids\": [\"32881070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The Cxcl1-Cxcl2 heterodimer is more potent at neutrophil recruitment than either individual chemokine; the heterodimer binds glycosaminoglycans with higher affinity than Cxcl1 or Cxcl2 alone and shows dampened CXCR2 receptor activity relative to its strong recruitment activity, suggesting optimal GAG interactions combined with dampened receptor desensitization promote robust recruitment.\",\n      \"method\": \"In vivo peritoneal neutrophil recruitment, CXCR2 cellular activity assays, GAG binding assays, flow cytometry\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods, single lab\",\n      \"pmids\": [\"37625009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCL2 (MIP-2) acting on CXCR2 induces dose-dependent neurotoxicity in primary rat motor neurons; this toxicity is abrogated by the CXCR1/2 inhibitor reparixin and is absent in motor neurons from CXCR2-deficient mice, demonstrating direct CXCR2-dependent motor neuron death.\",\n      \"method\": \"Primary motor neuron cultures, pharmacological inhibition (reparixin), CXCR2 knockout mouse neurons, immunocytochemistry\",\n      \"journal\": \"Neuroimmunomodulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (CXCR2-KO) and pharmacological (reparixin) validation of receptor-dependent mechanism in primary cells\",\n      \"pmids\": [\"18391506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IC-activated neutrophils express high levels of CXCL2, which amplifies neutrophil recruitment and activation in an autocrine/paracrine manner; neutralization of CXCL2 (but not CXCL1) in the interstitium effectively reduced neutrophil recruitment, establishing a CXCL2-driven positive-feedback loop distinct from tissue-resident cell-derived CXCL1.\",\n      \"method\": \"Multiphoton intravital microscopy, in vivo neutralizing antibodies, genomic approaches\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo neutralizing antibody with intravital imaging, single lab\",\n      \"pmids\": [\"26802238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Neutrophils produce Cxcl2 (but not Cxcl1) in response to bacteria (GBS and other species) via multiple endosomal TLRs requiring UNC93B1 chaperone; simultaneous absence of TLR7, 9, and 13 recapitulates UNC93B1-defective phenotype; neutrophil-derived Cxcl2 acts autocrinously to amplify its own production and enhance antibacterial activities including oxygen radical release.\",\n      \"method\": \"Cell depletion experiments, UNC93B1-deficient mice, TLR7/9/13 triple KO mice, in vitro stimulation, in vivo peritonitis model\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (multiple KO lines) and functional approaches with in vitro/in vivo orthogonal validation\",\n      \"pmids\": [\"31852751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL2 produced by rotavirus-infected hepatic macrophages (not cholangiocytes) is the essential mediator of neutrophil chemotaxis; anti-Mip2/Cxcl2 antibodies completely prevented neutrophil chemotaxis induced by conditioned media from infected macrophages.\",\n      \"method\": \"In vitro infection of cell lines, conditioned media chemotaxis assay, neutralizing antibody depletion, PCR, ELISA, immunostaining\",\n      \"journal\": \"Pediatric research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody depletion of specific chemokine with functional readout, single lab\",\n      \"pmids\": [\"20234283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pregnane X receptor (PXR) suppresses CXCL2 transcription through both NF-κB and AP-1 binding sites in the Cxcl2 promoter; mutation of both NF-κB and AP-1 sites abolished PXR-dependent suppression in reporter assays; PXR agonist treatment in vivo reduced hepatic Cxcl2 expression and neutrophil infiltration.\",\n      \"method\": \"Reporter assays with wild-type and mutated Cxcl2 promoter, in vivo mouse treatment, qRT-PCR\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — promoter mutagenesis in reporter assay plus in vivo confirmation, single lab\",\n      \"pmids\": [\"33076328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ERK2-dependent activation of c-Jun is required for NTHi-induced CXCL2 upregulation in inner ear spiral ligament fibrocytes; two AP-1 motifs in the CXCL2 5'-flanking region serve as NTHi-responsive elements, with the proximal AP-1 motif showing higher binding affinity for NTHi-activated c-Jun; CXCL2 release from fibrocytes recruits polymorphonuclear cells to the cochlea.\",\n      \"method\": \"MEK1/ERK2 inhibition, c-Jun knockdown, promoter binding analysis, chemotaxis assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding analysis, pharmacological inhibition, and functional chemotaxis assay, single lab\",\n      \"pmids\": [\"22379036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Daidzein suppresses TNF-α-induced Cxcl2 transcription in murine lung epithelial cells by inhibiting PARP-1 activity, which reduces RelA/p65 protein PARylation required for NF-κB-driven Cxcl2 promoter activation; PARP-1 overexpression enhanced Cxcl2 promoter activity which was blocked by daidzein.\",\n      \"method\": \"Reporter assays (NF-κB-luc, Cxcl2-luc), PARP-1 expression plasmid transfection, Western blot/immunoprecipitation for PARylation, PARP-1 activity assay, in vivo mouse model\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — enzymatic activity assay, reporter assay with overexpression, in vivo confirmation, single lab\",\n      \"pmids\": [\"24632845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A nucleus-localized lncRNA (lnc-Cxcl2) transcribed from the Cxcl2 gene locus acts in cis to inhibit Cxcl2 transcription in mouse lung epithelial cells by binding to the Cxcl2 promoter and recruiting ribonucleoprotein La, which inhibits chromatin accessibility; lnc-Cxcl2-deficient mice show increased Cxcl2 expression and more severe lung inflammation after influenza infection. (NOTE: This finding is about the lncRNA product, not the CXCL2 protein itself.)\",\n      \"method\": \"lnc-Cxcl2-deficient mice, chromatin accessibility assays, promoter binding analysis, RNA immunoprecipitation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — but this describes a non-protein (lncRNA) product and its regulation of CXCL2; excluded from canonical protein mechanism per rules\",\n      \"pmids\": [\"34607953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The secreted pseudo-serine protease PRSS35 suppresses CXCL2 protein levels through targeted proteolytic cleavage of a tandem lysine (KK) recognition motif on CXCL2; PRSS35 is processed by proprotein convertases to generate its active form; CXCL2 degradation by PRSS35 attenuates neutrophil recruitment and NET formation in HCC.\",\n      \"method\": \"In vitro protease cleavage assay, site-directed mutagenesis of cleavage motif, proprotein convertase assays, in vivo tumor models, immunoprecipitation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro cleavage reconstitution with mutagenesis of recognition motif plus in vivo functional validation\",\n      \"pmids\": [\"36934105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Macrophage-derived extracellular vesicles carry CXCL2 on their surface, which recruits neutrophils in vitro and in vivo; CXCL2 on macrophage EVs activates the CXCR2/PKC/NOX4 signaling pathway in neutrophils to induce tissue damage.\",\n      \"method\": \"EV isolation, CXCL2 knockdown in macrophages, in vitro neutrophil chemotaxis, in vivo sepsis model, Western blot\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EV isolation with CXCL2 manipulation, in vitro and in vivo functional validation, single lab\",\n      \"pmids\": [\"34507947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL2-CXCR2 axis in CPT-11-resistant colon cancer cells signals through Gαi-2 and Gαq/11 G-proteins to promote cancer stem cell properties (CSC markers, EMT markers, MMPs); CXCL2 shRNA knockdown reduced CSC protein expression, cyclins, EMT markers, G-protein levels, and MMP expression.\",\n      \"method\": \"shRNA knockdown, double immunofluorescence, Western blot, colony-formation assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — shRNA knockdown with multiple molecular readouts identifying G-protein pathway, single lab\",\n      \"pmids\": [\"30552676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Bone marrow adipocyte-conditioned media is a significant source of CXCL1 and CXCL2; both recombinant CXCL1 and CXCL2 accelerate osteoclast maturation via CXCR2 signaling, an effect blockable by neutralizing antibodies to either chemokine or by CXCR2 antagonist.\",\n      \"method\": \"In vitro osteoclastogenesis assay, adipocyte-conditioned media, neutralizing antibodies, CXCR2 antagonist, in vivo diet-induced adiposity models\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assay with receptor antagonist and neutralizing antibodies, in vivo correlations, single lab\",\n      \"pmids\": [\"25802102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL2 synthesized by oral squamous cell carcinoma cells promotes osteoclastic bone resorption by upregulating RANKL expression in stromal cells; anti-human CXCL2 neutralizing antibody dose-dependently blocked osteoclast induction by cancer cell-conditioned medium; recombinant CXCL2 directly increased RANKL expression in UAMS-32 stromal cells.\",\n      \"method\": \"Co-culture osteoclastogenesis assay, neutralizing antibody, recombinant CXCL2 treatment, in vivo xenograft model, microarray, immunohistochemistry\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blockade and recombinant protein in vitro plus in vivo xenograft validation, single lab\",\n      \"pmids\": [\"22771802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL2 inhibits osteoblast differentiation through inhibition of the ERK1/2 MAPK signaling pathway; ERK1/2 activation abolishes the inhibitory effect of CXCL2 on osteoblasts, while ERK1/2 inactivation reverses the pro-osteogenic effect of CXCL2 inhibition; CXCL2 neutralization in bone marrow alleviates bone loss in vivo.\",\n      \"method\": \"CXCL2 overexpression/knockdown in osteoblasts, ERK1/2 pharmacological activation/inhibition, in vivo antibody neutralization, Western blot, differentiation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with pathway rescue experiments and in vivo neutralization, single lab\",\n      \"pmids\": [\"31292171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL2-CXCR2 signaling mediates colon cancer cell adhesion to ECM proteins (vitronectin, fibronectin, fibrinogen) via αV integrin in a CXCR2-dependent manner; immunoneutralization of αV integrin abolished CXCL2-triggered adhesion and inhibited peritoneal metastasis by 69% in vivo; CXCR2 antagonist reduced metastatic nodules by 70%.\",\n      \"method\": \"In vitro migration/proliferation assays, ECM adhesion assay, integrin subunit antibody blockade, in vivo peritoneal metastasis mouse model, CXCR2 antagonist (SB225002)\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor antagonist, integrin neutralization, and in vivo model with multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"34115261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Pressure force-induced CXCL2 and CCL2 expression in osteoblasts requires the IL-1β-MyD88 signaling axis; MyD88-/- osteoblasts fail to upregulate CXCL2 after pressure force; anti-IL-1β antibody impairs pressure-induced CXCL2 mRNA increases and MAP kinase phosphorylation in wild-type but not MyD88-/- osteoblasts.\",\n      \"method\": \"MyD88-/- primary osteoblasts, neutralizing anti-IL-1β antibody, recombinant IL-1β stimulation, MAP kinase phosphorylation assay, qRT-PCR\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus antibody neutralization and recombinant cytokine rescue, single lab\",\n      \"pmids\": [\"25603464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Constitutive CXCL2/MIP-2 expression in normal mice is restricted to bone marrow and specifically to a Gr-1high, CD11b+, CD62Lhigh, CXCR2+ granulocyte subset (4-6% of total BM cells); in vitro BM stimulation does not increase the number of CXCL2-positive granulocytes; constitutive CXCL2 and CXCL1/KC expression patterns are tissue-specific and non-overlapping.\",\n      \"method\": \"RT-PCR, FACS analysis with intracellular staining, in vitro BM stimulation\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FACS with intracellular protein and surface marker co-staining, validated by RT-PCR across tissues, single lab\",\n      \"pmids\": [\"15466452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Commensal bacteria selectively upregulate CXCL2 (but not CXCL1) in periodontal tissue in a MyD88-dependent manner, increasing neutrophil recruitment; neutrophil recruitment to gingival tissue is entirely CXCR2-dependent; germ-free mice show reduced CXCL2 but intact CXCL1 expression.\",\n      \"method\": \"Germ-free mice, CXCR2-KO mice, MyD88-KO mice, quantitative analysis of neutrophils and chemokines in gingival tissue\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic KO models with tissue-level chemokine and cell quantification, single lab\",\n      \"pmids\": [\"23433011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IFNγ directly suppresses CXCL2 transcription in microglia and CNS-infiltrating myeloid cells, and suppresses CXCR2 transcription in CNS-infiltrating neutrophils; CXCL2 directly stimulates its own expression in neutrophils (autocrine/paracrine loop) enhanced by IL-1 and suppressed by IFNγ, determining anatomical location of CNS inflammatory infiltrates in EAE.\",\n      \"method\": \"IFNγR-KO mice, bone marrow chimeric mice, in vitro cultured neutrophils and macrophages with stimuli, qPCR, flow cytometry, immunohistochemistry, in situ hybridization\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mice, BM chimeras, in vitro mechanistic validation, and multiple orthogonal methods; IFNγ-CXCL2 autocrine loop directly tested\",\n      \"pmids\": [\"30012158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HIF-1α activation (induced by cancer cell-secreted Ref-1) in Schwann cells induces CXCL2 expression; Schwann cell-derived CXCL2 drives macrophage migration via CXCR2; conditional knockdown of CXCL2 in Schwann cells attenuates cancer cell-induced macrophage recruitment and mechanical hypersensitivity in vivo.\",\n      \"method\": \"Co-culture assays, recombinant CXCL2, CXCR2 antagonist, anti-CXCL2 antibody, conditional Schwann cell CXCL2 knockdown, in vivo breast cancer perineural model\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional cell-type-specific knockdown in vivo plus in vitro receptor blockade, single lab\",\n      \"pmids\": [\"36754246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCR2 physically associates with AMPA-type glutamate receptors (GluR1) as shown by co-immunoprecipitation in p7 cerebellar granule neurons and in HEK cells co-expressing both receptors; this association inhibits CXCL2-mediated chemotaxis, providing a molecular mechanism for the developmental loss of CXCL2 responsiveness in neurons.\",\n      \"method\": \"Co-immunoprecipitation, chemotaxis assay, CXCR2-expressing HEK cell transfection, primary cerebellar granule neuron cultures\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of CXCR2-AMPAR complex with functional chemotaxis consequence, single lab\",\n      \"pmids\": [\"12507773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NFATc3 transcription factor regulates CXCL2 gene expression in macrophages; CXCL2 promoter-pGL3 luciferase reporter activity is enhanced by NFATc3 co-transfection; exogenous recombinant CXCL2 restores pulmonary fibrosis phenotype in NFATc3+/- mice, placing CXCL2 downstream of NFATc3 in macrophage-driven fibrosis.\",\n      \"method\": \"NFATc3 KO mice, luciferase reporter assay with NFATc3 co-transfection, adoptive macrophage transfer, in vitro cytokine stimulation, recombinant CXCL2 rescue experiment\",\n      \"journal\": \"Aging and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay, genetic KO, adoptive transfer, and functional rescue, single lab\",\n      \"pmids\": [\"37523510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL2 binding to the glomerular endothelial glycocalyx is mediated by heparan sulfate (HS) in a domain-specific manner; CXCL2 and CXCL1 do not compete for the same HS binding sites on glomerular endothelial cells, with differential affinities determined by distinct HS domain structures, shown by competition ELISA with anti-HS scFv antibodies.\",\n      \"method\": \"Competition ELISA with HS preparations and anti-HS scFv antibodies on mouse glomerular endothelial cells (mGEnC-1)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific blocking with validated anti-HS antibodies, in vitro binding assay, single lab\",\n      \"pmids\": [\"30248108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCL1 (KC) is required upstream of CXCL2 (MIP-2) expression in the lung during Klebsiella pneumoniae infection; KC-/- mice show reduced CXCL2 expression and diminished NF-κB and MAPK activation; in bone marrow-derived and alveolar macrophages, neutralizing KC decreases bacteria-induced MIP-2 production and NF-κB/MAPK activation.\",\n      \"method\": \"KC-/- mice, bone marrow-derived and alveolar macrophage cultures, KC neutralization, NF-κB/MAPK signaling assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and in vitro neutralization approaches, single lab\",\n      \"pmids\": [\"20937845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CXCL2 overexpression in HCC cells induces apoptosis via both nuclear and mitochondrial apoptosis pathways and negatively regulates the cell cycle via ERK1/2 signaling; CXCL2 overexpression in vivo inhibited subcutaneous tumor growth in nude mice.\",\n      \"method\": \"Lentiviral overexpression, in vitro proliferation/apoptosis assays, ERK1/2 pathway analysis, in vivo xenograft model\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with pathway analysis and in vivo validation, single lab\",\n      \"pmids\": [\"30293547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TIARP (a six-transmembrane protein) suppresses CXCL2 production by fibroblast-like synoviocytes and reduces CXCR1/CXCR2 expression on neutrophils; TIARP-/- FLS showed enhanced CXCL2 production upon TNF-α stimulation, and TIARP-/- neutrophils showed enhanced CXCL2-driven migration; IL-6R blockade in TIARP-/- mice attenuated arthritis and diminished neutrophil CXCL2-driven recruitment.\",\n      \"method\": \"TIARP-/- mice, DNA microarray, in vitro migration assay, anti-IL-6R antibody treatment, K/BxN serum transfer arthritis model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, in vitro functional assay, and in vivo therapeutic blockade, single lab\",\n      \"pmids\": [\"27995997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CXCL2 secreted by microglia via CXCR2 promotes hippocampal neuronal ferroptosis (elevated MDA, decreased glutathione, iron accumulation, altered ferroptosis protein expression); rmCXCL2 induces microglia self-activation through CXCR2-NF-κB/NLRP3 signaling; CXCR2 antagonist SB225002 reverses CXCL2-induced ferroptosis.\",\n      \"method\": \"Recombinant CXCL2 treatment of neurons, CXCR2 antagonist (SB225002), ferroptosis markers (MDA, GSH, iron, protein levels), NF-κB/NLRP3 signaling assays, in vivo CLP model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — recombinant protein and receptor antagonist with multiple molecular readouts, single lab\",\n      \"pmids\": [\"39216299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-532-5p directly targets CXCL2 mRNA (validated by luciferase reporter assay) and negatively regulates CXCL2 expression in HCC; CXCL2 promotes HCC cell proliferation and metastasis, and miR-532-5p-mediated inhibition of these phenotypes is reversed by CXCL2 overexpression.\",\n      \"method\": \"Luciferase reporter assay (miR-532-5p target validation), miRNA overexpression/inhibition, cell proliferation and metastasis assays\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct luciferase reporter validation of miRNA targeting plus functional rescue, single lab\",\n      \"pmids\": [\"26807173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"11β-HSD1 in cardiac fibroblasts suppresses CXCL2 (and CXCL5) expression; fibroblast fractions from Hsd11b1-/- hearts show elevated Cxcl2 post-MI; corticosterone or 11-dehydrocorticosterone (11β-HSD1 substrate) provision to cultured cardiac fibroblasts suppresses IL-1α-induced CXCL2 expression; bone marrow chimeras show this effect is attributable to host (non-bone marrow) cells.\",\n      \"method\": \"Hsd11b1-/- mice, bone marrow chimeras, cardiac fibroblast culture with glucocorticoid treatment, gene expression analysis\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, BM chimeras, and direct in vitro fibroblast treatment, single lab\",\n      \"pmids\": [\"28522730\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL2 is a secreted CXC chemokine that functions primarily as a potent neutrophil chemoattractant by binding and activating CXCR2 (via both G-protein and β-arrestin pathways) and interacting with heparan sulfate glycosaminoglycans in a domain-specific manner; it exists as monomers, homodimers, and Cxcl1-Cxcl2 heterodimers with distinct receptor potencies and GAG affinities; its transcription is regulated by NF-κB, STAT1, AP-1, Fli-1, NFATc3, SIRT2/MKP-1, and PXR acting on defined promoter elements; it is produced by neutrophils (via endosomal TLR/UNC93B1 signaling), macrophages (including via TRPM2 channel), mast cells (preformed in granules and newly synthesized via TLR4), fibroblasts, and other cells; it drives autocrine/paracrine positive-feedback loops in neutrophils amplifying its own production; it is presented by ACKR1 at endothelial junctions to guide neutrophil transmigration; it promotes osteoclastogenesis via RANKL upregulation and ERK/NF-κB pathways while inhibiting osteoblast differentiation via ERK1/2 suppression; it can be proteolytically degraded by the secreted protease PRSS35 at a tandem KK motif; its CXCR2-mediated signaling activates downstream pathways including PKC/MAPK, PI3K/AKT, and NLRP3 inflammasome in diverse cellular contexts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CXCL2 is a secreted CXC chemokine that functions as a potent neutrophil chemoattractant, acting through the receptor CXCR2 to direct innate immune cell trafficking and to amplify inflammation [#1, #28]. It is produced by mast cells (preformed in granules and newly synthesized via TLR4), tissue macrophages, neutrophils, fibroblasts, microglia, and other cell types, and these distinct sources stage sequential and self-amplifying waves of neutrophil recruitment [#1, #13]. Neutrophil-derived CXCL2 establishes an autocrine/paracrine positive-feedback loop that amplifies its own production and enhances antibacterial functions including oxygen radical release [#13, #12, #29]. During transmigration, CXCL2 deposited by migrating neutrophils is captured by the atypical chemokine receptor ACKR1 at endothelial junctions to create a chemokine depot that drives unidirectional luminal-to-abluminal migration, a role functionally distinct from CXCL1 [#0]. CXCL2 exists as monomers, homodimers, and Cxcl1-Cxcl2 heterodimers with distinct CXCR2 potencies and heparan-sulfate affinities, and neutrophil recruitment is determined by the combined interplay of receptor activation and domain-specific glycosaminoglycan binding rather than either alone [#9, #10, #33]. Through CXCR2, CXCL2 couples to G-protein and \\u03b2-arrestin pathways and engages downstream PKC/MAPK, integrin-linked kinase, and NLRP3 inflammasome signaling in diverse contexts [#9, #8]. CXCL2 transcription is driven by NF-\\u03baB together with STAT1, AP-1/c-Jun, c-Fos, Fli-1, and NFATc3 acting on defined promoter elements, and is restrained by regulators including PXR, SIRT2/MKP-1, and IFN\\u03b3 [#2, #4, #16, #7, #32, #15, #5, #29]. Beyond immunity, CXCL2 drives osteoclastogenesis by upregulating stromal RANKL and inhibits osteoblast differentiation through ERK1/2 suppression [#23, #24], and is degraded extracellularly by the secreted protease PRSS35 at a tandem lysine motif to limit neutrophil recruitment and NET formation [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing where CXCL2 is constitutively made was needed to distinguish baseline from inflammation-induced expression; mapping it to a defined bone marrow granulocyte subset showed CXCL2 production is cell-type-restricted and not simply inducible.\",\n      \"evidence\": \"RT-PCR and intracellular FACS with surface marker co-staining across mouse tissues\",\n      \"pmids\": [\"15466452\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the functional role of constitutive CXCL2 in the marrow granulocyte subset\", \"No mechanism for tissue-restricted expression pattern\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linking CXCL2 induction to specific upstream signaling resolved how pathogen and danger stimuli converge on the gene; p38 MAPK-IKK-NF-\\u03baB and P2X7-driven NFAT/PKC-MAPK pathways were shown to drive CXCL2 transcription in dendritic cells and microglia.\",\n      \"evidence\": \"Pharmacological inhibitors, siRNA, NF-\\u03baB KO mice, reporter and chemotaxis assays\",\n      \"pmids\": [\"18985311\", \"20477948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab, single-stimulus contexts\", \"Relative contribution of parallel pathways not quantified in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating direct recruitment of c-Fos and p65 to the CXCL2 promoter and linking macrophage CXCL2 to bone destruction connected transcriptional control to a pathological osteoclast phenotype.\",\n      \"evidence\": \"ChIP, signaling inhibitors, neutralizing antibodies, in vivo bone destruction model, osteoclastogenesis assays\",\n      \"pmids\": [\"21507677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ROS requirement for secretion vs mRNA not mechanistically resolved\", \"Promoter occupancy kinetics not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining the cellular choreography of CXCL2 release answered how recruitment is initiated and sustained: mast cell granules and macrophages provide sequential CXCL1/CXCL2 sources, and microbial/IL-1\\u03b2 stimuli engage NF-\\u03baB/STAT1 in tissue cells.\",\n      \"evidence\": \"Mast cell-deficient and macrophage-depleted mice, neutralizing antibodies, intravital microscopy, promoter mutagenesis, ChIP, germ-free and MyD88-KO mice\",\n      \"pmids\": [\"23645836\", \"24280128\", \"23433011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCL1 vs CXCL2 functional non-redundancy not fully dissected\", \"Promoter findings tied to specific cell types only\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolving CXCL2's spatial role in transmigration showed it is not merely a soluble gradient: ACKR1 captures neutrophil-derived CXCL2 at endothelial junctions to enforce directional migration, distinguishing it from CXCL1.\",\n      \"evidence\": \"Confocal intravital microscopy, cell-specific knockout mice, neutralizing antibodies\",\n      \"pmids\": [\"30446388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ACKR1-CXCL2 presentation not defined\", \"How the depot is released to abluminal side unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Characterizing the biophysical interplay of receptor and matrix binding answered why monomer/dimer/heterodimer forms differ functionally; CXCL2 oligomeric state and domain-specific heparan sulfate binding jointly set recruitment potency.\",\n      \"evidence\": \"Competition ELISA with anti-HS antibodies, CXCR2 G-protein/\\u03b2-arrestin assays, HS binding assays, in vivo recruitment\",\n      \"pmids\": [\"30248108\", \"32881070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural map of distinct HS-binding domains incomplete\", \"In vivo oligomeric equilibrium not directly measured\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying neutrophil endosomal TLR/UNC93B1 control of CXCL2 and the IFN\\u03b3 brake explained how the CXCL2 autocrine loop is selectively triggered and spatially constrained during infection and CNS inflammation.\",\n      \"evidence\": \"UNC93B1-deficient and TLR7/9/13 triple-KO mice, IFN\\u03b3R-KO mice, BM chimeras, in vitro/in vivo stimulation\",\n      \"pmids\": [\"31852751\", \"30012158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity for CXCL2 over CXCL1 mechanism incomplete\", \"Endosomal signaling-to-promoter link not fully traced\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defining the Cxcl1-Cxcl2 heterodimer as the most potent recruiter and identifying PRSS35 as an extracellular protease established both a gain-of-function ligand species and a post-secretion off-switch for CXCL2.\",\n      \"evidence\": \"In vivo neutrophil recruitment, GAG binding/CXCR2 assays, in vitro cleavage reconstitution with motif mutagenesis, proprotein convertase assays, tumor models\",\n      \"pmids\": [\"37625009\", \"36934105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of heterodimer-CXCR2 dampening not solved\", \"Physiological abundance and regulation of PRSS35-mediated turnover unquantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CXCL2 oligomeric state, GAG presentation, ACKR1 depots, and extracellular proteolysis are integrated in vivo to set the magnitude and spatial precision of neutrophil recruitment remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified structural/quantitative model linking ligand form to receptor signaling output\", \"Direct in vivo measurement of CXCL2 monomer/dimer/heterodimer ratios lacking\", \"Generality of PRSS35 turnover across tissues unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [9, 11, 25, 30]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [9, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 13, 20, 19]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 8, 21]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 28]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CXCR2\", \"ACKR1\", \"PRSS35\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}